CD 11b and CD56 As Prognostic Markers in Acute Myeloid Leukemia | ||||
| Journal of Current Medical Research and Practice | ||||
| Volume 9, Issue 1, January 2024, Page 25-34 PDF (988.36 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/jcmrp.2024.346794 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Shaaban Helal  ; Eman M. Salah Eldin; Zeinab A. Kamel
| ||||
| Department of Clinical Pathology, Faculty of Medicine, Assiut University, Assiut, Egypt | ||||
| Abstract | ||||
| Background: Acute myeloid leukemia (AML) is a common adult leukemia and is characterized by a differentiation block and aberrant clonal growth of hematopoietic blasts. Aim: This study aims: 1-To detect CD56 and CD11b marker expression in newly diagnosed adult AML cases. 2-To study the correlation between CD56 and CD11b expression with haematological parameters in cases of adult AML. Materials and Methods: The study was conducted on 26 newly diagnosed AML cases presented to the flow cytometry unit, Clinical Pathology department, Assiut University Hospital, from November 2018 to October 2019. Their ages ranged from 23 to 85 years, including 13 males and 13 females. The patients were diagnosed with Acute Myeloid leukemia after Bone marrow Aspirate and Immunophenotyping. Results: It was noticed that patients with relapse had the highest expression of CD11b and CD56, whereas patients who achieved remission had the lowest expression of CD11b and CD56. Conclusion: The present study showed that CD11b positivity and CD56 were a helpful indicator of chemoresistance and a poor prognostic marker in AML patients. | ||||
| Keywords | ||||
| acute myeloid leukemia; CD11b; CD56; Immunophenotyping | ||||
|
Statistics Article View: 24 PDF Download: 11 |
||||
